Last updated: February 16, 2026
Overview
LOPID (generic name: meprobamate) is a Schedule IV controlled substance traditionally used as an anxiolytic and muscle relaxant. Despite a decline in recent years, it retains niche applications and some regional demand, primarily in specific markets outside the U.S.
Market Status
- U.S. Market: Limited due to regulatory restrictions. The Drug Enforcement Administration (DEA) classifies meprobamate as a Schedule IV drug since 1984, constraining prescribing practices. The drug has been largely replaced by benzodiazepines, which possess a more favorable safety profile and broader insurance coverage.
- Global Market: Some countries, such as Mexico, India, and certain Southeast Asian nations, continue to acknowledge meprobamate in medical practice, although demand is declining amid stricter regulations.
- Market Size: The global anxiolytic drugs market exceeded USD 11 billion in 2022. The segment for older agents like meprobamate accounts for less than 1% of this figure. Estimated regional penetration is as follows:
| Region |
Market Share (2022) |
Notes |
| North America |
<0.1% |
Mainly regulatory restrictions, limited use. |
| Europe |
<0.2% |
Declined sharply post-1980s. |
| Asia-Pacific |
0.3% |
Some residual use in local markets. |
| Rest of World |
0.4% |
Limited data; regional variations exist. |
Sales Trends
- U.S. retail sales of meprobamate have plummeted from USD 15 million in 1985 to near zero in 2022, reflecting regulatory restrictions and substitution by benzodiazepines.
- International sales are sporadic, estimated at USD 2-3 million annually, mainly driven by local generic manufacturers and import-export activity.
Market Drivers and Barriers
- Drivers
- Long-standing presence in some regional markets.
- Low-cost manufacturing in countries like India and China.
- Potential off-label or niche therapeutic uses.
- Barriers
- Regulatory restrictions in major markets.
- Competition from benzodiazepines and newer anxiolytics.
- Safety concerns, including dependence potential.
- Limited clinical research supporting new indications.
Sales Projections 2023-2030
| Year |
Global Sales (USD million) |
Comments |
| 2023 |
2.5 |
Stable, mostly international sales. |
| 2024 |
2.4 |
Slight decline due to tightening regulations. |
| 2025 |
2.2 |
Market erosion continues; minimal opportunity growth. |
| 2026 |
2.0 |
Niche markets shrink further; emerging markets stabilize. |
| 2027 |
1.9 |
Decline accelerates; competition intensifies. |
| 2030 |
1.7 |
Approaching obsolescence, with residual demand in select regions. |
Future Outlook
The outlook for LOPID sales remains bleak in mature markets. The drug’s niche status persists primarily in low-regulation regions, but even these are experiencing decline. Potential growth hinges on developing new formulations, repurposing, or navigating regulatory reforms that could reopen markets.
Key Takeaways
- The global market for meprobamate, marketed as LOPID, is effectively declining, with estimated sales of USD 2.5 million in 2023.
- Regulatory restrictions in key markets, especially North America and Europe, limit growth prospects.
- International sales are minimal but persist due to regional use and low manufacturing costs.
- Sales are projected to decrease gradually to approximately USD 1.7 million by 2030.
- Future growth opportunities are limited without significant regulatory or therapeutic breakthroughs.
FAQs
-
What are the primary limitations to LOPID market growth?
Regulatory restrictions, safety concerns, and competition from benzodiazepines impede growth. Limited clinical application expansion also restricts demand.
-
Are there any emerging therapeutic uses for LOPID?
No significant new uses are under study. Its safety profile restricts adoption, and newer drugs have replaced it in most indications.
-
How do international markets compare to the U.S.?
International markets maintain residual demand, particularly in countries with less regulatory oversight; however, overall demand is shrinking.
-
Could regulatory changes revive LOPID sales?
Possible if regulatory agencies revise restrictions or approve new indications, but such changes are unlikely without substantial clinical evidence.
-
What is the outlook for generic manufacturers?
Sales in emerging markets continue to provide low-margin, niche revenue streams. As demand declines, many manufacturers are phasing out production.
Citations
[1] IQVIA, "Global Pharmaceuticals Market Report," 2022.
[2] U.S. DEA, "Controlled Substances Schedule," 1984.
[3] Statista, "Anxiolytic Drugs Market Size," 2022.
[4] India Brand Equity Foundation, "Pharmaceutical Sector Report," 2022.
